Remimazolam and Scoliosis Orthopedics (rimazolam)
Primary Purpose
Benzodiazepines
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Remimazolam
Propofol
Sponsored by
About this trial
This is an interventional treatment trial for Benzodiazepines
Eligibility Criteria
Criteria:
Inclusion Criteria:
- Age greater than 18 years and less than 60 years
- Elective scoliosis orthopaedic surgery under general anesthesia.
- ASA Physical Score I-III
- Signed informed consent.
Exclusion Criteria:
- Patients who cannot understand the method and requirements of the arousal test and cannot cooperate in completing the arousal test.
- Patients with limb sensory-motor dysfunction.
- Patients with a history of severe neurological disorders.
- Patients with psychiatric disorders.
- Patients who have taken benzodiazepines and/or opioids daily for one month or intermittently for the last three months.
- Patients with concomitant severe respiratory and circulatory disorders, including acute heart failure, unstable angina, resting ECG heart rate <50 beats/min, QTc: ≥ 470ms in men and ≥ 480ms in women, third-degree AV block, severe arrhythmia, moderate to severe heart valve disease, chronic obstructive pulmonary disease, and history of asthma.
- Abnormal liver and kidney function: ALT and/or AST exceeding 2.5 times the upper limit of the medical reference range; urea or urea nitrogen ≥1.5 × ULN, blood creatinine greater than the upper limit of normal values.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
remimazolam group
propoful group
Arm Description
For induction of anesthesia, rimazolam benzoate was pumped at a rate of 12 mg/kg/h; for maintenance of anesthesia, 1.0-2.0 mg/kg/h rimazolam was given as a continuous pump.
For induction of anesthesia, propofol medium-length chain fatty milk injection 2 mg/kg was given by intravenous push; for maintenance of anesthesia, 6-8 mg/kg/h propofol medium-length chain fatty milk injection was given by continuous pumping.
Outcomes
Primary Outcome Measures
Mean time to arousal
the time between the cessation of intraoperative drug infusion and the subject's ability to move the toes on command.
Secondary Outcome Measures
Quality of arousal
Class I: the patient wakes up when called, is quiet and moves the limbs as instructed; Class II, the patient wakes up suddenly, moves the limbs involuntarily, does not endanger the internal fixation and tracheal tube, and can move the limbs as instructed; Class III, the patient wakes up suddenly, moves the trunk violently and requires pressure to not endanger the internal fixation and tracheal tube
Proportion of successful induction of anesthesia
The criteria for successful induction of anesthesia were that both of the following two requirements were met: completion of tracheal intubation; and no use of remedial sedative drugs
Mean time from initiation of dosing to MOAA/S score ≤1
Mean time from initiation of dosing to MOAA/S score ≤1
Mean time from discontinuation at the end of surgery to full awakening of the subject
time to the first of three consecutive MOAA/S scores of 5
EEG characteristics during the induction, maintenance and awakening periods
EEG power in alpha band, beta band, theta band, and gamma band
Full Information
NCT ID
NCT05519371
First Posted
August 16, 2022
Last Updated
August 25, 2022
Sponsor
Beijing Chao Yang Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05519371
Brief Title
Remimazolam and Scoliosis Orthopedics
Acronym
rimazolam
Official Title
Efficacy and Safety Evaluation of Injectable Remimazolam for Intraoperative Arousal in Scoliosis Orthopedics
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2022 (Anticipated)
Primary Completion Date
October 1, 2022 (Anticipated)
Study Completion Date
October 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Chao Yang Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Spinal cord injury is one of the most dangerous complications of scoliosis orthopedic surgery, and the Stagnara awakening test has been used in orthopedic spine surgery and is considered the "gold standard" for detecting spinal cord injury. During the awakening test, the patient is awakened from anesthesia and, in conjunction with a neurological assessment, moves his or her fingers and toes to determine the integrity of spinal cord motor function in order to avoid spinal cord injury. During this procedure, the patient still requires a degree of sedation and analgesia to tolerate tracheal intubation and surgical pain. Remazolam benzoate for injection is a new class of benzodiazepines that are ultra-short-acting sedative/anesthetic drugs. It has the advantages of rapid onset, rapid elimination, and no drug accumulation by continuous infusion, and has the advantage of being applied to wake up during spinal orthopedic surgery, but its effectiveness and safety are still unclear. This study aims to elucidate the safety and efficacy of rimazolam benzoate for injection for arousal in spinal orthopedic surgery through a single-center, randomized, single-blind, positive drug-controlled trial, with the aim of providing a basis for the development of a safe and effective anesthetic protocol for such surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Benzodiazepines
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
148 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
remimazolam group
Arm Type
Experimental
Arm Description
For induction of anesthesia, rimazolam benzoate was pumped at a rate of 12 mg/kg/h; for maintenance of anesthesia, 1.0-2.0 mg/kg/h rimazolam was given as a continuous pump.
Arm Title
propoful group
Arm Type
Active Comparator
Arm Description
For induction of anesthesia, propofol medium-length chain fatty milk injection 2 mg/kg was given by intravenous push; for maintenance of anesthesia, 6-8 mg/kg/h propofol medium-length chain fatty milk injection was given by continuous pumping.
Intervention Type
Drug
Intervention Name(s)
Remimazolam
Intervention Description
During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h
During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped.
Intervention Type
Drug
Intervention Name(s)
Propofol
Intervention Description
During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
Primary Outcome Measure Information:
Title
Mean time to arousal
Description
the time between the cessation of intraoperative drug infusion and the subject's ability to move the toes on command.
Time Frame
Perioperative period
Secondary Outcome Measure Information:
Title
Quality of arousal
Description
Class I: the patient wakes up when called, is quiet and moves the limbs as instructed; Class II, the patient wakes up suddenly, moves the limbs involuntarily, does not endanger the internal fixation and tracheal tube, and can move the limbs as instructed; Class III, the patient wakes up suddenly, moves the trunk violently and requires pressure to not endanger the internal fixation and tracheal tube
Time Frame
Perioperative period
Title
Proportion of successful induction of anesthesia
Description
The criteria for successful induction of anesthesia were that both of the following two requirements were met: completion of tracheal intubation; and no use of remedial sedative drugs
Time Frame
Perioperative period
Title
Mean time from initiation of dosing to MOAA/S score ≤1
Description
Mean time from initiation of dosing to MOAA/S score ≤1
Time Frame
Perioperative period
Title
Mean time from discontinuation at the end of surgery to full awakening of the subject
Description
time to the first of three consecutive MOAA/S scores of 5
Time Frame
Perioperative period
Title
EEG characteristics during the induction, maintenance and awakening periods
Description
EEG power in alpha band, beta band, theta band, and gamma band
Time Frame
Perioperative period
Other Pre-specified Outcome Measures:
Title
Other adverse events
Description
Other adverse events within 28 days after surgery were noted
Time Frame
Postoperative 28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Criteria:
Inclusion Criteria:
Age greater than 18 years and less than 60 years
Elective scoliosis orthopaedic surgery under general anesthesia.
ASA Physical Score I-III
Signed informed consent.
Exclusion Criteria:
Patients who cannot understand the method and requirements of the arousal test and cannot cooperate in completing the arousal test.
Patients with limb sensory-motor dysfunction.
Patients with a history of severe neurological disorders.
Patients with psychiatric disorders.
Patients who have taken benzodiazepines and/or opioids daily for one month or intermittently for the last three months.
Patients with concomitant severe respiratory and circulatory disorders, including acute heart failure, unstable angina, resting ECG heart rate <50 beats/min, QTc: ≥ 470ms in men and ≥ 480ms in women, third-degree AV block, severe arrhythmia, moderate to severe heart valve disease, chronic obstructive pulmonary disease, and history of asthma.
Abnormal liver and kidney function: ALT and/or AST exceeding 2.5 times the upper limit of the medical reference range; urea or urea nitrogen ≥1.5 × ULN, blood creatinine greater than the upper limit of normal values.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Remimazolam and Scoliosis Orthopedics
We'll reach out to this number within 24 hrs